Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Antengene Corporation Secures $980M Global Licensing Deal with K2 Therapeutics for CDH6×CD3 Bispecific T-Cell Engager

Fineline Cube Jun 22, 2026
Company Deals

CSPC Innovation Pharmaceutical Files Hong Kong IPO Prospectus Following Strategic Evolution from Caffeine Producer to Biopharmaceutical Player

Fineline Cube Jun 22, 2026
Company Deals

Zhiyi Biotechnology Files Hong Kong IPO Prospectus as China’s Leading Live Biotherapeutic Products Developer

Fineline Cube Jun 22, 2026
Company Deals

Dawnrays Pharmaceutical Launches RMB 200 Million Biopharma Venture Fund with Shanghai Jianxin Partners

Fineline Cube Jun 22, 2026
Company Deals

Insilico Medicine and SK Biopharmaceuticals Launch $2.5B AI Drug Discovery Collaboration Targeting Neuroimmune Diseases

Fineline Cube Jun 22, 2026
Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

Fineline Cube Jun 17, 2026
Company Drug

Gan & Lee Pharmaceuticals Secures UAE Approval for Insulin Glargine Prefilled Pen, Expanding Global Diabetes Portfolio

Fineline Cube Jun 22, 2026
Company Drug

Mabwell Bioscience Presents Promising Phase I/II Data for Nectin-4 ADC Bulumtatug Fuvedotin in Cervical Cancer at ESMO-GC

Fineline Cube Jun 22, 2026
Company Drug

CanSino Biologics Receives NMPA Approval for DTcP Hib MCV4 Combined Vaccine

Fineline Cube Feb 25, 2025

China-based vaccine specialist CanSino Biologics Inc. (HKG: 6185) announced that its absorbed diphtheria, tetanus, acellular...

Company Deals

MGI Tech Partners with Oncoclínicas&Co to Advance Precision Medicine in Brazil

Fineline Cube Feb 25, 2025

China-based gene sequencing specialist MGI Tech Co., Ltd (SHA: 688114) has partnered with OC Medicina...

Company Drug

Boehringer Ingelheim’s Nerandomilast Receives NMPA Review for IPF Treatment

Fineline Cube Feb 25, 2025

Boehringer Ingelheim announced that its investigational drug nerandomilast has been accepted for review by the...

Company Drug

QYuns Therapeutics’ QX002N Meets Primary Endpoint in AS Phase III Study

Fineline Cube Feb 25, 2025

China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) announced that its Phase III study of...

Company Drug

Takeda’s Takhzyro Receives EMA Approval for New Administration Form in HAE Patients

Fineline Cube Feb 25, 2025

Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) announced that the European Medicines Agency (EMA) has approved...

Policy / Regulatory

National Allied Procurement Office Allows VBP Winners to Adjust MAH and Manufacturing Details

Fineline Cube Feb 24, 2025

The National Allied Procurement Office has issued a notification clarifying rules for China’s Volume-Based Procurement...

Company

Ipsen Posts 8.7% Revenue Growth in 2024, Driven by Rare Diseases and Oncology

Fineline Cube Feb 24, 2025

French biopharma firm Ipsen (EPA: IPN, OTCMKTS: IPSEY) reported an 8.7% year-on-year (YOY) increase in...

Company Drug

Meyer FSMP Hong Kong Secures NMPA Approval for First FSMP in Greater China

Fineline Cube Feb 24, 2025

Hong Kong-based Meyer FSMP Hong Kong Limited, an oncology-focused foods for special medical purpose (FSMP)...

Company Deals Drug

Pfizer Halts Global Development of Hemophilia B Gene Therapy Beqvez Amid Limited Demand

Fineline Cube Feb 24, 2025

Pfizer Inc. (NYSE: PFE) has terminated the development and commercialization of Beqvez (fidanacogene elaparvovec), its...

Company Deals

Jointown Pharmaceutical Partners with Shandong DYNE to Boost Pediatric Drug Distribution

Fineline Cube Feb 24, 2025

Jointown Pharmaceutical Group Co., Ltd (SHA: 600998), China’s largest private pharmaceutical distributor, has partnered with...

Company Drug

CSPC Pharmaceutical Initiates Phase III Trial for Ammuxetine in Depression Treatment

Fineline Cube Feb 24, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced the start of a Phase III clinical...

Company Medical Device

Subtle Medical Integrates DeepSeek with FDA-Approved SupMR AI Platform

Fineline Cube Feb 24, 2025

Shanghai-based Subtle Medical Inc., an AI-powered medical imaging firm operating in the U.S. and China,...

Company Deals

AWS Collaborates with MSK to Accelerate Oncology Research via AI and Cloud Tech

Fineline Cube Feb 24, 2025

Amazon Web Services (AWS) announced a strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK),...

Company Deals

Cholesgen Raises Over RMB100M in Series A to Advance Metabolic Disease Pipelines

Fineline Cube Feb 24, 2025

China-based glycolipid metabolism specialist Cholesgen (Shanghai) Co. Ltd. has reportedly raised over RMB100 million ($13.8...

Company Drug

Innorna’s IN013 Receives FDA Rare Pediatric Designation for Wilson’s Disease Treatment

Fineline Cube Feb 24, 2025

Shenzhen-based Innorna Co., Ltd, a platform company leveraging mRNA and lipid nanoparticle (LNP) delivery technologies,...

Company Deals

Amoytop Biotech to Acquire Skyline Therapeutics’ Gene Therapy Assets for $15M Plus Milestones

Fineline Cube Feb 24, 2025

Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has announced plans to acquire partial assets of...

Company

Novo Nordisk’s Emerging Business Division VP Eve Jiang Departs for External Opportunities

Fineline Cube Feb 24, 2025

Jiang Yiwei (Eve Jiang), corporate vice president (CVP) of Novo Nordisk’s (NYSE: NVO) Emerging Business...

Company Drug

Joyo Pharma’s JYP0015 Receives CDE Approval for RAS Mutation Cancer Trials

Fineline Cube Feb 24, 2025

China’s Center for Drug Evaluation (CDE) has tacitly approved Joyo Pharma’s Category 1 drug JYP0015,...

Company Drug

Zhejiang Huahai Pharma’s HB0056 Receives NMPA Approval for Asthma Trials

Fineline Cube Feb 24, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that its bispecific antibody HB0056 has...

Company Drug

Zhejiang Dian Diagnostics Partners with Best Covered to Tackle Alzheimer’s Disease

Fineline Cube Feb 24, 2025

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a China-based medical diagnostics firm, has formed a...

Posts pagination

1 … 228 229 230 … 686

Recent updates

  • Antengene Corporation Secures $980M Global Licensing Deal with K2 Therapeutics for CDH6×CD3 Bispecific T-Cell Engager
  • CSPC Innovation Pharmaceutical Files Hong Kong IPO Prospectus Following Strategic Evolution from Caffeine Producer to Biopharmaceutical Player
  • Zhiyi Biotechnology Files Hong Kong IPO Prospectus as China’s Leading Live Biotherapeutic Products Developer
  • Gan & Lee Pharmaceuticals Secures UAE Approval for Insulin Glargine Prefilled Pen, Expanding Global Diabetes Portfolio
  • Mabwell Bioscience Presents Promising Phase I/II Data for Nectin-4 ADC Bulumtatug Fuvedotin in Cervical Cancer at ESMO-GC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Antengene Corporation Secures $980M Global Licensing Deal with K2 Therapeutics for CDH6×CD3 Bispecific T-Cell Engager

Company Deals

CSPC Innovation Pharmaceutical Files Hong Kong IPO Prospectus Following Strategic Evolution from Caffeine Producer to Biopharmaceutical Player

Company Deals

Zhiyi Biotechnology Files Hong Kong IPO Prospectus as China’s Leading Live Biotherapeutic Products Developer

Company Drug

Gan & Lee Pharmaceuticals Secures UAE Approval for Insulin Glargine Prefilled Pen, Expanding Global Diabetes Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.